SSA
ONC

Schonfeld Strategic Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,000
Closed -$8.71M – 2611
2021
Q3 		$8.71M Buy
+24,000
New +$7.85M 0.09% 293

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Schonfeld Strategic Advisors's ONC Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in BeOne Medicines Ltd (ONC) in Q2 2026: 1,932 shares worth $551K. The stake represents ﹤0.01% of the portfolio and ranks #1771 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ONC as recently as Q1 2025.

Schonfeld Strategic Advisors first reported a position in ONC in Q4 2019 and has held it in 8 quarters since. The position peaked at $14M in Q1 2025. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Schonfeld Strategic Advisors held 1,932 shares of BeOne Medicines Ltd worth $551K as of Q2 2026.
  • BeOne Medicines Ltd was a new Schonfeld Strategic Advisors position in Q2 2026.
  • BeOne Medicines Ltd made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1771 holding.
  • Schonfeld Strategic Advisors first reported a position in BeOne Medicines Ltd in Q4 2019 and has held it in 8 quarters since.
  • Schonfeld Strategic Advisors's BeOne Medicines Ltd position peaked at $14M in Q1 2025.
  • 283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.